Biogen Inc. (BIIB)

Biogen's stock price has significantly declined over the past year and six months. Key events impacting the stock include Q4 2024 earnings and 2025 guidance, which projected a revenue decline, an analyst downgrade by Truist due to growth concerns, a manufacturing investment announcement in North Carolina, and clinical data presentations at scientific conferences. The company reported strong fourth-quarter 2024 results, beating earnings and sales estimates. Biogen announced its intention to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. Biogen has announced upcoming scientific presentations at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, including 48-month results for LEQEMBI and insights into a subcutaneous formulation. They also presented positive interim Phase 1 results for salanersen (BIIB115/ION306) for spinal muscular atrophy in July 2025, leading to plans for registrational studies. In June 2025, Biogen initiated a Phase 3 study of felzartamab for primary membranous nephropathy.

Demand for Biogen's products, particularly its multiple sclerosis (MS) drugs, exhibits some seasonality. The first quarter of the year is typically a seasonally weaker period for the MS business. Sales of Spinraza, for spinal muscular atrophy, have also been affected by decreased demand amid competitive pressure in the U.S. and pricing pressure in ex-U.S. markets. Historically, the company's seasonality profile indicates that July has a higher chance of closing higher than the previous month.

Biogen Inc. is a multinational biotechnology company focused on discovering, developing, manufacturing, and delivering therapies for serious neurological and neurodegenerative diseases. The company's product portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, plaque psoriasis, Friedreich's Ataxia and postpartum depression. Biogen is also involved in biosimilars and has products for certain lymphomas and other conditions.

Biogen's global headquarters are in Cambridge, Massachusetts. The company has significant manufacturing presence in the United States, particularly in North Carolina's Research Triangle Park, and a biologics factory in Switzerland. It is consolidating ex-U.S. fill-finish capabilities in Europe into one site in Ireland. Biogen's commercial footprint spans nearly 90 countries across the Americas, Europe, and Asia.

Biogen has historically demonstrated a strong commitment to corporate responsibility and sustainability. In the past year, Biogen's reputation has been positively influenced by advancements in Alzheimer's research, pipeline development, and manufacturing investments. Plans for a new global headquarters and innovation hub in Kendall Square, Cambridge, by 2028, aim to foster collaboration and innovation.

Biogen Inc. has a mixed ownership structure including institutional, insider, and retail investors. Institutional investors hold a significant portion of the company's stock. Major institutional owners include Vanguard Group Inc, PRIMECAP Management Company, BlackRock, Inc., and State Street Corp.